Literature DB >> 29985971

Computational analysis of kinase inhibitor selectivity using structural knowledge.

Yu-Chen Lo1, Tianyun Liu1,2, Kari M Morrissey3, Satoko Kakiuchi-Kiyota4, Adam R Johnson5, Fabio Broccatelli6, Yu Zhong4, Amita Joshi3, Russ B Altman1,2.   

Abstract

Motivation: Kinases play a significant role in diverse disease signaling pathways and understanding kinase inhibitor selectivity, the tendency of drugs to bind to off-targets, remains a top priority for kinase inhibitor design and clinical safety assessment. Traditional approaches for kinase selectivity analysis using biochemical activity and binding assays are useful but can be costly and are often limited by the kinases that are available. On the other hand, current computational kinase selectivity prediction methods are computational intensive and can rarely achieve sufficient accuracy for large-scale kinome wide inhibitor selectivity profiling.
Results: Here, we present a KinomeFEATURE database for kinase binding site similarity search by comparing protein microenvironments characterized using diverse physiochemical descriptors. Initial selectivity prediction of 15 known kinase inhibitors achieved an >90% accuracy and demonstrated improved performance in comparison to commonly used kinase inhibitor selectivity prediction methods. Additional kinase ATP binding site similarity assessment (120 binding sites) identified 55 kinases with significant promiscuity and revealed unexpected inhibitor cross-activities between PKR and FGFR2 kinases. Kinome-wide selectivity profiling of 11 kinase drug candidates predicted novel as well as experimentally validated off-targets and suggested structural mechanisms of kinase cross-activities. Our study demonstrated potential utilities of our approach for large-scale kinase inhibitor selectivity profiling that could contribute to kinase drug development and safety assessment. Availability and implementation: The KinomeFEATURE database and the associated scripts for performing kinase pocket similarity search can be downloaded from the Stanford SimTK website (https://simtk.org/projects/kdb). Supplementary information: Supplementary data are available at Bioinformatics online.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29985971      PMCID: PMC6330000          DOI: 10.1093/bioinformatics/bty582

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  48 in total

1.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

2.  A quantitative analysis of kinase inhibitor selectivity.

Authors:  Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

3.  Exploring uncharted territories: predicting activity cliffs in structure-activity landscapes.

Authors:  Rajarshi Guha
Journal:  J Chem Inf Model       Date:  2012-08-16       Impact factor: 4.956

Review 4.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

Authors:  S K Hanks; A M Quinn; T Hunter
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

Review 5.  The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

Authors:  Josep Tabernero
Journal:  Mol Cancer Res       Date:  2007-03       Impact factor: 5.852

6.  Inverse in silico screening for identification of kinase inhibitor targets.

Authors:  Stefan Zahler; Simon Tietze; Frank Totzke; Michael Kubbutat; Laurent Meijer; Angelika M Vollmar; Joannis Apostolakis
Journal:  Chem Biol       Date:  2007-11

7.  Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.

Authors:  Milica Momcilovic; Sean T Bailey; Jason T Lee; Michael C Fishbein; Clara Magyar; Daniel Braas; Thomas Graeber; Nicholas J Jackson; Johannes Czernin; Ethan Emberley; Matthew Gross; Julie Janes; Andy Mackinnon; Alison Pan; Mirna Rodriguez; Melissa Works; Winter Zhang; Francesco Parlati; Susan Demo; Edward Garon; Kostyantyn Krysan; Tonya C Walser; Steven M Dubinett; Saman Sadeghi; Heather R Christofk; David B Shackelford
Journal:  Cell Rep       Date:  2017-01-17       Impact factor: 9.995

8.  KNIME-CDK: Workflow-driven cheminformatics.

Authors:  Stephan Beisken; Thorsten Meinl; Bernd Wiswedel; Luis F de Figueiredo; Michael Berthold; Christoph Steinbeck
Journal:  BMC Bioinformatics       Date:  2013-08-22       Impact factor: 3.169

9.  Advancing the activity cliff concept, part II.

Authors:  Dagmar Stumpfe; Antonio de la Vega de León; Dilyana Dimova; Jürgen Bajorath
Journal:  F1000Res       Date:  2014-03-18

10.  Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential.

Authors:  Yu-Chen Lo; Silvia Senese; Bryan France; Ankur A Gholkar; Robert Damoiseaux; Jorge Z Torres
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

View more
  2 in total

1.  Target-specific compound selectivity for multi-target drug discovery and repurposing.

Authors:  Tianduanyi Wang; Otto I Pulkkinen; Tero Aittokallio
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

Review 2.  An overview of kinase downregulators and recent advances in discovery approaches.

Authors:  Beilei Wang; Hong Wu; Chen Hu; Haizhen Wang; Jing Liu; Wenchao Wang; Qingsong Liu
Journal:  Signal Transduct Target Ther       Date:  2021-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.